FDA.reportPublic FDA data

Byooviz 10 MG/ML per 0.05 ML Injection

RxCUI
2602359
RxNorm name
Byooviz 10 MG/ML per 0.05 ML Injection
Display name
Byooviz 10 MG/ML per 0.05 ML Injection
Full name
Byooviz 10 MG/ML per 0.05 ML Injection
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:25

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761202Byoovizranibizumab-nuna351(k) InterchangeableRx2026-06-01

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
e46db299-edd1-4457-89b2-c1e2e505f1b0Byooviz 10 MG/ML per 0.05 ML InjectionSY14These highlights do not include all the information needed to use BYOOVIZ safely and effectively. See full prescribing information for BYOOVIZ. BYOOVIZ ® (ranibizumab-nuna) injection, for intravitreal use Initial U.S. Approval: 2021 BYOOVIZ (ranibizumab-nuna) is biosimilar 1 to LUCENTIS (ranibizumab injection) 1 - Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there a20251201
e46db299-edd1-4457-89b2-c1e2e505f1b0Byooviz 0.5 MG per 0.05 ML InjectionSY14These highlights do not include all the information needed to use BYOOVIZ safely and effectively. See full prescribing information for BYOOVIZ. BYOOVIZ ® (ranibizumab-nuna) injection, for intravitreal use Initial U.S. Approval: 2021 BYOOVIZ (ranibizumab-nuna) is biosimilar 1 to LUCENTIS (ranibizumab injection) 1 - Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there a20251201
e46db299-edd1-4457-89b2-c1e2e505f1b0Byooviz 0.5 MG in 0.05 ML InjectionPSN14These highlights do not include all the information needed to use BYOOVIZ safely and effectively. See full prescribing information for BYOOVIZ. BYOOVIZ ® (ranibizumab-nuna) injection, for intravitreal use Initial U.S. Approval: 2021 BYOOVIZ (ranibizumab-nuna) is biosimilar 1 to LUCENTIS (ranibizumab injection) 1 - Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there a20251201
e46db299-edd1-4457-89b2-c1e2e505f1b00.05 ML ranibizumab-nuna 10 MG/ML Injection [Byooviz]SBD14These highlights do not include all the information needed to use BYOOVIZ safely and effectively. See full prescribing information for BYOOVIZ. BYOOVIZ ® (ranibizumab-nuna) injection, for intravitreal use Initial U.S. Approval: 2021 BYOOVIZ (ranibizumab-nuna) is biosimilar 1 to LUCENTIS (ranibizumab injection) 1 - Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there a20251201
77b53b2c-da0e-44b2-ade4-b08ff75a7584Byooviz 0.5 MG per 0.05 ML InjectionSY1These highlights do not include all the information needed to use BYOOVIZ safely and effectively. See full prescribing information for BYOOVIZ. BYOOVIZ ® (ranibizumab-nuna) injection, for intravitreal use Initial U.S. Approval: 2021 BYOOVIZ (ranibizumab-nuna) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences be20251126
77b53b2c-da0e-44b2-ade4-b08ff75a7584Byooviz 10 MG/ML per 0.05 ML InjectionSY1These highlights do not include all the information needed to use BYOOVIZ safely and effectively. See full prescribing information for BYOOVIZ. BYOOVIZ ® (ranibizumab-nuna) injection, for intravitreal use Initial U.S. Approval: 2021 BYOOVIZ (ranibizumab-nuna) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences be20251126
77b53b2c-da0e-44b2-ade4-b08ff75a75840.05 ML ranibizumab-nuna 10 MG/ML Injection [Byooviz]SBD1These highlights do not include all the information needed to use BYOOVIZ safely and effectively. See full prescribing information for BYOOVIZ. BYOOVIZ ® (ranibizumab-nuna) injection, for intravitreal use Initial U.S. Approval: 2021 BYOOVIZ (ranibizumab-nuna) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences be20251126
77b53b2c-da0e-44b2-ade4-b08ff75a7584Byooviz 0.5 MG in 0.05 ML InjectionPSN1These highlights do not include all the information needed to use BYOOVIZ safely and effectively. See full prescribing information for BYOOVIZ. BYOOVIZ ® (ranibizumab-nuna) injection, for intravitreal use Initial U.S. Approval: 2021 BYOOVIZ (ranibizumab-nuna) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences be20251126